Obesity has become a widespread public health crisis, demanding effective strategies for its management. Until recently, healthcare providers faced limited pharmaceutical options for obesity treatment. However, since 2012, the United States Food and Drug Administration (FDA) has approved four drugs for weight loss and maintenance, marking a significant advancement in the field. Saxenda, manufactured by Novo Nordisk, is one of these medications, offering a new avenue for chronic weight management alongside a reduced-calorie diet and physical activity. This article delves into the specifics of Saxenda, its mechanism of action, clinical trial results, potential side effects, and overall efficacy as a weight loss treatment.
Understanding Obesity and the Need for Pharmacotherapy
Obesity is not merely a cosmetic concern; it's a serious medical condition associated with a heightened risk of numerous illnesses, including type 2 diabetes, hypertension, cardiovascular disease, and certain cancers. The World Health Organization (WHO) recognizes obesity as a global epidemic, emphasizing the urgent need for effective interventions.
Successful non-surgical treatment of obesity typically involves a multidisciplinary approach encompassing nutrition, behavioral modification, exercise, and, in some cases, medical management with pharmacotherapy. While lifestyle interventions are often the first line of defense, they can be difficult to sustain long-term, leading to weight regain for many individuals. In such cases, drug therapy, like Saxenda, can serve as a valuable adjunct to lifestyle changes, helping patients achieve and maintain clinically significant weight loss.
Pharmacotherapy for weight management is generally considered for individuals with a BMI of 30 kg/m2 or greater, or those with a BMI of 27 kg/m2 or greater who also have at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus (T2DM), or dyslipidemia, and who have not achieved success with lifestyle interventions alone.
What is Saxenda?
Saxenda is an injectable prescription medicine approved by the FDA for chronic weight management in adults and children (12-17 years) with obesity. It contains liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, as its active ingredient. Liraglutide is also the active ingredient in Victoza, another Novo Nordisk product approved for treating type 2 diabetes in adults, but at a lower dose.
Read also: Comprehensive Look at Saxenda and Ozempic
How Saxenda Works
Liraglutide mimics the effects of GLP-1, a naturally occurring hormone in the body. GLP-1 is secreted by intestinal L cells and the brain stem, and its receptors are found in various organs, including the stomach, pancreas, intestine, and central nervous system (CNS).
GLP-1 plays a crucial role in regulating appetite and glucose metabolism. Specifically, liraglutide, by acting as a GLP-1 receptor agonist, works in several ways to promote weight loss:
- Stimulates insulin release: It enhances insulin secretion from the pancreas in response to elevated blood glucose levels, helping to lower blood sugar.
- Regulates glucagon release: It suppresses glucagon secretion, another hormone that raises blood sugar levels.
- Slows gastric emptying: It delays the rate at which food empties from the stomach, leading to a feeling of fullness and reduced appetite.
- Affects appetite in the brain: It acts on GLP-1 receptors in the CNS, particularly in the hypothalamus and brain stem, to reduce hunger and increase satiety.
In essence, Saxenda helps regulate appetite by increasing feelings of fullness and satiety while reducing hunger and prospective food consumption.
Clinical Evidence: The LEAD and SCALE Programs
The effectiveness of liraglutide for weight loss has been extensively studied in several clinical trial programs, most notably the Liraglutide Effect and Action in Diabetes (LEAD) and the Satiety and Clinical Adiposity, Liraglutide Evidence (SCALE) programs.
LEAD Program
The LEAD program primarily focused on evaluating the efficacy and safety of liraglutide in patients with type 2 diabetes. While weight loss was not the primary endpoint, these trials demonstrated that liraglutide was associated with a modest weight reduction (approximately 3%) compared to placebo or other antidiabetic drugs.
Read also: Comprehensive Saxenda Information
One notable trial within the LEAD program was DURATION-6, which compared 1.8mg liraglutide daily with sustained-release exenatide 2mg once weekly in patients with T2DM.
SCALE Program
The SCALE program was specifically designed to investigate the effects of liraglutide on weight management in individuals with overweight or obesity, both with and without type 2 diabetes.
SCALE Diabetes
The SCALE Diabetes trial, a 56-week randomized, double-blind, placebo-controlled study, involved patients with type 2 diabetes. The results showed that approximately half of the participants receiving 3.0mg liraglutide experienced a weight loss of 5% or more of their body weight, compared to 35.6% in the liraglutide 1.8mg group and 13.8% in the placebo group.
SCALE Obesity and Prediabetes
The SCALE Obesity and Prediabetes trial included a larger cohort of participants without type 2 diabetes who had a BMI of 30kg/m2 or more, or a BMI of 27kg/m2 or more with treated or untreated dyslipidemia or hypertension. This study also found that a significant proportion of participants treated with liraglutide achieved clinically meaningful weight loss.
SCALE Maintenance
The SCALE Maintenance trial assessed the long-term effects of liraglutide on weight maintenance. The findings indicated that 81.4% of participants receiving liraglutide maintained at least 5% or more of their initial weight loss, compared to only 48.9% in the placebo group. Furthermore, about half of the participants in the liraglutide group continued to lose more weight during the maintenance phase.
Read also: Saxenda: Comprehensive Guide
SCALE Sleep Apnea
The SCALE Sleep Apnea trial explored the impact of liraglutide on obstructive sleep apnea (OSA). The study revealed that the mean reduction in the apnea-hypopnea index (AHI) was significantly greater with liraglutide than with placebo, suggesting that weight loss induced by liraglutide can improve OSA-related parameters.
Additional Research
Beyond the LEAD and SCALE programs, other studies have corroborated the weight loss efficacy of liraglutide. A 20-week randomized, double-blind, placebo-controlled trial by Astrup et al. demonstrated that individuals with obesity (BMI 30-40kg/m2) without T2DM experienced significantly greater weight loss with liraglutide compared to placebo. The mean weight loss with liraglutide at doses of 1.2mg, 1.8mg, 2.4mg, and 3.0mg was 4.8kg, 5.5kg, 6.3kg, and 7.2kg, respectively, compared to 2.8kg with placebo.
Dosage and Administration
Saxenda is administered via subcutaneous injection once daily. The recommended injection sites are the abdomen, thigh, or upper arm. To minimize gastrointestinal side effects, the dosage is gradually increased over several weeks, following a specific dose escalation chart.
The typical starting dose is 0.6mg daily, which is increased weekly by 0.6mg until the maintenance dose of 3mg daily is reached, usually around week 5. Patients who experience intolerance to a dose increase may delay the escalation for an additional week.
According to prescribing information, physicians should evaluate patients after 16 weeks of treatment with Saxenda. If a patient has not lost at least 4% of their initial body weight by this time, it is unlikely that the medication will be effective, and discontinuation should be considered.
Potential Side Effects and Contraindications
Like all medications, Saxenda can cause side effects. The most common side effects observed in clinical trials include:
- Nausea
- Diarrhea
- Constipation
- Vomiting
- Hypoglycemia (low blood sugar)
- Decreased appetite
These side effects are generally mild to moderate and tend to subside over time. However, some individuals may experience more severe side effects, such as:
- Pancreatitis (inflammation of the pancreas)
- Gallbladder problems (including gallstones)
- Kidney problems (related to dehydration)
- Increased heart rate
- Depression or suicidal thoughts
- Serious allergic reactions
Saxenda carries a boxed warning regarding the risk of thyroid C-cell tumors. Liraglutide has been shown to cause dose-dependent and treatment duration-dependent thyroid C-cell tumors in rodents. However, it is unknown whether Saxenda causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.
Saxenda is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should be counseled about the potential risk of MTC and informed about the symptoms of thyroid tumors, such as a mass in the neck, dysphagia, dyspnea, or persistent hoarseness.
Patient Perspectives and Real-World Experiences
Patient input from various organizations, including Obesity Canada, Diabetes Canada, and the Gastrointestinal (GI) Society, highlights the challenges faced by individuals living with obesity. Many patients express frustration with the impact of obesity on their overall quality of life, including social stigma and difficulty sustaining weight loss efforts.
While diet and exercise are often the first-line treatments, many individuals struggle to maintain these lifestyle changes long-term. Medications like Saxenda offer a potential solution, but concerns about side effects, cost, and access to prescriptions remain.
Patient groups emphasize that individuals are often less focused on improved weight than on improved health-related comorbidities (e.g., diabetes, hypertension, and sleep apnea) as well as outcomes related to everyday life such as productivity, energy levels, sleep, activity, and mental health.
Real-world reviews of Saxenda reveal a range of experiences. Some patients report significant weight loss, reduced appetite, and improved overall well-being, while others experience bothersome side effects or underwhelming results. It's important to note that individual responses to Saxenda can vary, and what works for one person may not work for another.
Considerations for Prescribing and Monitoring Saxenda
When considering Saxenda as a treatment option, healthcare providers should carefully evaluate the patient's medical history, current medications, and potential risk factors. Patients should be thoroughly informed about the potential benefits and risks of Saxenda, as well as the importance of adhering to a reduced-calorie diet and regular physical activity.
Monitoring during treatment with Saxenda is crucial to assess efficacy and identify any potential side effects. Weight loss response should be evaluated after 12 to 16 weeks at the maximum dose. A clinically meaningful weight loss of 5% to 10% of total body weight is typically associated with improved metabolic parameters.
Treatment discontinuation should be considered if the patient experiences intolerable side effects or does not achieve adequate weight loss. Decisions about treatment duration are influenced by patientsâ preferences, side effects, and rare but serious adverse effects such as pancreatitis, worsening in mood, or increase in anxiety.